Conatus rises on Histogen's application for facial wrinkles treatment

Histogen

20/04/2020 15:58

** Biotech co's  CNAT.O  shares rise 7.9% to 36 cents
    ** CNAT's merger partner, Histogen Inc, says it submitted an
application to U.S. FDA to begin an early-stage clinical trial
of HST 002, its treatment for facial folds and wrinkles 
    ** Histogen said in January it would merge with CNAT in an
all-stock deal; combined co to be led by Histogen’s current
management team and will keep the name Histogen Inc 
    ** CNAT shares down 2.37% YTD 

 (Reporting by Vishwadha Chander in Bengaluru)
 ((vishwadha.chander@thomsonreuters.com))